Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.68 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Normeperidine SCHEMBL4540908 | 0.98 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Normeperidine SCHEMBL8177568 | 0.98 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Normeperidine SCHEMBL4537496 | 0.98 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Normeperidine SCHEMBL27449404 | 0.92 | OPRM1 (0.85) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL17187978 | 0.91 | OPRM1 (0.84) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL23225662 | 0.89 | OPRM1 (0.79) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL6866343 | 0.88 | OPRM1 (0.79) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL8187471 | 0.88 | OPRM1 (0.78) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL11094110 | 0.86 | OPRM1 (0.75) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL23225663 | 0.86 | OPRM1 (0.75) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 549 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| CN-112375030-A | Preparation method of diphenoxylate hydrochloride | 常州康普药业有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-110573159-A | D-methadone and derivatives thereof for the treatment of disorders of the nervous system | 保罗·L·曼佛雷蒂 | 2019-12-13 | — | — | CN | claimed |
| EP-2716659-B1 | IMMUNOASSAYS FOR MEPERIDINE AND METABOLITES | RANDOX LABORATORIES LTD (GB) | 2018-08-29 | — | — | EP | claimed |
| WO-2018144551-A2 | COMPOUNDS FOR TREATMENT OR PREVENTION OF DISORDERS OF THE NERVOUS SYSTEM AND SYMPTOMS AND MANIFESTATIONS THEREOF, AND FOR CYTO-PROTECTION AGAINST DISEASES AND AGING OF CELLS, AND SYMPTOMS AND MANIFESTATIONS THEREOF | MANFREDI PAOLO L (US) | 2018-08-09 | — | — | WO | claimed |
| US-20180214395-A1 | Compounds for Treatment or Prevention of Disorders of the Nervous System and Symptoms and Manifestations Thereof, and for Cyto-Protection Against Diseases and Aging of Cells, and Symptoms and Manifestations Thereof | MANFREDI PAOLO L (US) | 2018-08-02 | — | — | US | claimed |
| US-9863966-B2 | Immunoassays for meperidine and metabolites | RANDOX LABORATORIES LIMITED (GB) | 2018-01-09 | — | — | US | claimed |
| US-20170189902-A1 | READY-TO-CONSTITUTE ANALYTICAL PLATFORMS FOR CHEMICAL ANALYSES AND QUANTIFICATION | PINPOINT TESTING, LLC (US) | 2017-07-06 | — | — | US | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005098429-A2 | SYSTEM AND METHOD FOR REAL-TIME DIAGNOSIS, TREATMENT, AND THERAPEUTIC DRUG MONITORING | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050233459-A1 | Marker detection method and apparatus to monitor drug compliance | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2005-10-20 | — | — | US | claimed |
| US-20050054942-A1 | System and method for therapeutic drug monitoring | UNIVERSITY OF FLORIDA | 2005-03-10 | — | — | US | claimed |
| EP-1385421-A2 | IDENTIFICATION, DIAGNOSIS, AND TREATMENT OF NEUROPATHOLOGIES, NEUROTOXICITIES, TUMORS, AND BRAIN AND SPINAL CORD INJURIES USING MICROELECTRODES WITH MICROVOLTAMMETRY | The Research Foundation Of the City university of New York (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030032001-A1 | Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE | 2003-02-13 | — | — | US | claimed |
| WO-2002082970-A2 | DIAGNOSIS AND TREATMENT OF NEURAL DISEASE AND INJURY USING MICROVOLTAMMETRY | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2002-10-24 | — | — | WO | claimed |
| US-4297346-A | PSYCHOACTIVE DRUGS BONDED TO NEUROPEPTIDES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1981-10-27 | — | — | US | claimed |
| US-4086234-A | Process for the preparation of tertiary amines | G. D. SEARLE & CO. (US) | 1978-04-25 | — | — | US | claimed |
| US-4045442-A | ANTIINFLAMMATORY, ANTIDIARRHEA | G. D. SEARLE & CO. (US) | 1977-08-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214395-A1 | Compounds for Treatment or Prevention of Disorders of the Nervous System and Symptoms and Manifestations Thereof, and for Cyto-Protection Against Diseases and Aging of Cells, and Symptoms and Manifestations Thereof | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | OPRM1 2057/4885OPRD1 2177/4885OPRK1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.